Endometrial CXCL13 Expression Is Cycle Regulated in Humans and Aberrantly Expressed in Humans and Rhesus Macaques With Endometriosis by Franasiak, Jason M. et al.
Original Article
Endometrial CXCL13 Expression Is Cycle
Regulated in Humans and Aberrantly
Expressed in Humans and Rhesus Macaques
With Endometriosis
Jason M. Franasiak, MD1,*, Katherine A. Burns, PhD2,*,
Ov Slayden, PhD3, Lingwen Yuan, PhD4, Marc A. Fritz, MD4,
Kenneth S. Korach, PhD2, Bruce A. Lessey, MD, PhD5,
and Steven L. Young, MD, PhD4
Abstract
C-X-C ligand 13 (CXCL13), a regulator of mucosal immunity, is secreted by human endometrial epithelium and may be involved in
embryo implantation. However, cyclic expression of human endometrial CXCL13 in health and disease is not well studied. This
study examines cycle stage-specific endometrial CXCL13 expression in normal humans when compared to those with biopsy-
confirmed, stage 1 to 4 endometriosis using real-time reverse transcriptase, real-time polymerase chain reaction and immuno-
histochemistry. Eutopic endometrial CXCL13 expression was also compared between normal, control Rhesus macaques, and
macaques with advanced endometriosis. In healthy women, CXLC13 messenger RNA expression was minimal in the proliferative
phase and maximal in the secretory phase. However, in the presence of endometriosis, proliferative-phase endometrial expres-
sion markedly increased in both humans and rhesus subjects (P < .05). The cross-species and cross-stage concordance suggests a
pathophysiologic role for CXCL13 in endometriosis and its use as a biomarker for disease.
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Introduction
Endometriosis is a common, complex disease affecting about
5% to 10% of reproductive-age women and contributes to
chronic pelvic pain and infertility.1-4 Defined by the presence
of endometrial glands and stroma at extrauterine sites, endome-
triosis appears to alter the eutopic endometrial phenotype, with
the endometrium showing changes in molecular markers for
inflammation5,6 and steroid metabolism.7 Such eutopic endo-
metrial changes have been suggested as potential diagnostic
biomarkers for endometriosis.8-10 However, these markers
have, to date, been insufficiently sensitive and specific for
broad clinical use. Imaging has also been proposed as a diag-
nostic tool, but it also lacks sufficient sensitivity.11
Although a diagnosis of endometriosis may be suggested by
patient history, symptoms, and physical signs, clinical presen-
tation is variable and nonspecific. Given the shortcomings of
biomarkers, imaging, and clinical examination, surgical visua-
lization (with histologic confirmation) remains the only sensi-
tive and specific diagnostic test for endometriosis.12-15
The pathophysiology of endometriosis is still debated. Ret-
rograde menstruation and subsequent tissue persistence and
proliferation are a commonly accepted theory; however, the
incidence of retrograde menstruation is similar in women with
and without endometriosis.16 It is proposed that women who
develop endometriosis lesions have differences in the endome-
trial regulation of tissue proliferation, tissue remodeling,
inflammation, and other immune processes.17-22 Additionally,
it has been hypothesized that endometriosis-related pain and
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infertility results from an endometrial inflammatory response,
chemokine-mediated immune cell recruitment, and subsequent
chronic activation of the immune system.23,24
Cytokines and chemokines play critical roles in immune sys-
tem activation and function but have also been implicated in the
upregulation of adhesion molecules that promote cancer inva-
sion, in a manner analogous to that proposed for endometriosis
lesions.25,26 Furthermore, these inflammatory mediators may
direct alterations in immune surveillance that facilitates implan-
tation and survival of ectopic endometrial tissues.27,28 Thus, che-
mokines may play a functional role in the pathophysiology of
endometriosis and therefore may be a pertinent target for devel-
opment of novel diagnostic and therapeutic approaches.
In this article, the experiments are focused on expression of a
single chemokine, C-X-C ligand 13 (CXCL13). Possible endo-
metrial functions of CXCL13 include regulation of both immu-
nity and reproductive functions.29,30 In the pleural and
peritoneal cavities, CXCL13 is constitutively expressed by
macrophages and cells of nonhematopoietic origin. At these
sites, it is an important promoter of natural antibody production
and local immunity via specific chemoattraction of the B-1
subset of B cells,29 and mice homozygous for CXCL13 deletion
have a severe reduction in peritoneal and pleural B-1 cells.31
Interestingly, CXCL13 is also abundantly secreted by human
endometrial epithelium and is specifically taken up by embryos
with high implantation potential.32 Endometrial expression has
been shown to be elevated during the window of implantation
in women undergoing in vitro fertilization (IVF) versus those
in natural menstrual cycles.33 Additionally, microarray data are
suggestive of an increase in CXCL13 in the secretory phase,34
although microarray data are not consistent.35
With the aforementioned studies suggesting the importance
of CXCL13 in immunity and reproductive functions, we sought
to examine how endometriosis altered CXCL13 in women with
this disease. In this study, we examined the expression of the
CXCL13 chemokine by both reverse transcriptase, real-time
polymerase chain reaction (RT-PCR) and immunohistochemis-
try in endometrium across the menstrual cycle in normal,
reproductive-age women and then compared these findings to
expression in the endometrium of women collected prior to sur-
gical confirmation of endometriosis. The proliferative and
secretory phases were analyzed separately due to recent evi-
dence suggesting endometrial alterations in both phases in
women with endometriosis.36,37 Since factors altered in endo-
metriosis in multiple species are more likely to play a funda-
mental pathophysiological role in disease, we also present
data on CXCL13 expression in eutopic endometrium of Rhesus
macaques with and without naturally occurring endometriosis.
Materials and Methods
Participants
Study population and endometrial sampling. Participants signed an
informed consent for this institutional review board (IRB)-
approved protocol for office biopsy on normal women timed
to luteinizing hormone (LH) surge. Normal controls (n ¼ 50)
were recruited and included healthy volunteers between the
ages of 18 and 38 who had regular, cyclic menses. Regular
menses was defined as a cycle length of 24 to 35 days. None
had signs or symptoms of endometriosis or fertility problems,
defined by unprotected intercourse for greater than 1 year with-
out conception. Participants had been off of hormonal therapy
for a minimum of 3 months prior to biopsy. This clinical infor-
mation was obtained via a standardized questionnaire that was
reviewed by the study coordinator and principle investigator.
They did not undergo laparoscopy, but based upon prevalence
data, approximately 5% to 10% (3-5 of 50) of healthy women
would have undetected endometriosis to skew the findings
away from significance.38 All normal controls were sampled
only once.
Patients with endometriosis (n ¼ 27) came from a popula-
tion who originally carried the diagnosis of unexplained infer-
tility between the ages of 21.4 and 39.2. They were found to
have stage 1 to 4 endometriosis as confirmed via laparoscopic
inspection and pathologic diagnosis. Patients with endometrio-
sis had been off hormonal therapy for a minimum of 3 months
prior to biopsy. Cycle timing in all women was determined
relative to urinary LH rise. Endometrium was obtained by
endometrial suction curettage (3 mm flexible plastic instru-
ment) from controls and patients with endometriosis. Portions
of endometrial biopsies were frozen in liquid nitrogen in the
clinic and transported to the laboratory where they were stored
at 80C until further use, while the rest was fixed in 10%
buffered formalin for paraffin embedding and sectioning. All
tissues were obtained in accordance with the Committee for
the Protection of Human Subjects at the University of North
Carolina and Greenville Hospital System under approved IRB
protocols.
Messenger RNA expression. Expression of human endometrial
CXCL13 messenger RNA (mRNA) was determined using quan-
titative real-time RT-PCR (qRT-PCR) analysis. The qRT-PCR
was performed on an MX3000 real-time thermocycler (Strata-
gene, La Jolla, California) with the following conditions: total
RNA was extracted from frozen endometrial biopsies using Tri-
zol Reagent (Ambion, Life Technologies, Grand Island, New
York) according to the manufacturer’s suggested conditions.
RNA quantification was performed using RiboGreen (Invitro-
gen; Carlsbad, California) with a ribosomal RNA standard
curve. First strand cDNA was synthesized using AffinityScript
QPCR cDNA Synthesis Kit (Agilent Technologies, Santa Clara,
California) according to the manufacturer’s specifications.
Relative quantitation of specific mRNA species was
achieved by real-time PCR using predesigned Taqman probe
and primer sets (Applied Biosystems Inc, Foster City, Califor-
nia), and relative expression was calculated using the DDCt
method. The PCR primers and fluorogenic probes included
Hs04194521-s1 (peptidylprolyl isomerase A [PPIA]) and
Hs00757930-m1 (CXCL13; Applied Biosystems Inc). The
PPIA (cyclophilin A) gene was used as a constitutive house-
keeping control since previous work suggested that PPIA
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exhibits little variation across the menstrual cycle and disease
states (Steven L. Young, MD, PhD, unpublished data,
2014)—indeed, we saw little variation in Ct for PPIA across the
samples. Probe-primer sets were designed across exon–exon
junctions to prevent detection of genomic DNA. The data were
grouped by cycle phase and analyzed by Kruskal-Wallis non-
parametric testing for samples across the cycle and Dunn Mul-
tiple comparison test when comparing endometriosis and
control samples.
Immunohistochemistry. Immunohistochemistry for CXCL13 was
performed on paraffin sections of endometrium from women
with endometriosis and normal controls. All reactions were
performed at room temperature unless noted otherwise. Tissue
sections were deparaffinized in toluene, rehydrated through
descending ethanols, rinsed in phosphate-buffered saline
(PBS), and pretreated with 5% hydrogen peroxide in 83%
methanol for 30 minutes to block endogenous peroxidases.
Slides were incubated with normal rabbit serum (ABC-kit,
Vector Labs, Burlingame, California) for 30 minutes to block
nonspecific immunoglobulin (Ig) G reactions. Sections were
then incubated at 4C overnight in a humidity chamber with
a goat polyclonal antibody raised to detect CXCL13 (R&D
Systems; Minneapolis, Minnesota); primary antibody was
omitted from slides used as negative controls.
After overnight incubation with primary antibody, slides
were rinsed in PBS, incubated in normal rabbit serum for 10
minutes, and incubated with the 1:200 biotinylated rabbit anti-
goat IgG (Vector Labs) for 60 minutes. The slides were rinsed
with PBS and reacted with 1:400 avidin DH–biotinylated horse-
radish peroxidase H complex for 60 minutes and rinsed in PBS.
The slides were incubated for 10 minutes in diaminobenzidine
peroxidase substrate (Vector Labs) to visualize antibody–antigen
complexes. Sections were then stabilized by incubating the
slides in double-distilled water for 5 minutes. Slides were coun-
terstained with hematoxylin, dehydrated in ascending ethanols,
cleared through a series of xylene, and then sealed under Per-
mount. Images were taken with an SPOT Insight 4 camera using
a Nikon E600 Eclipse microscope (Melville, New York).
Macaque Subjects
Study population and endometrial sampling. In the initial phase,
endometrium was obtained from Rhesus macaques (Macaca
mulatta) with naturally occurring, advanced endometriosis
(similar to human stage 4; n ¼ 11) and normal controls (n ¼
7). These were obtained from previous studies conducted at the
Oregon National Primate Research Center (ONPRC).39,40 Ani-
mal care was provided by the veterinary staff of the ONPRC
Division of Comparative Medicine after review and approval
by the ONPRC Animal Care and Use Committee. To ensure
endometriosis-free control samples, animals were ovariecto-
mized and treated with Silastic capsules that release 17b-estra-
diol (E2; Sigma, St. Louis, Missouri) and E2 plus progesterone
to produce artificial menstrual cycles as described.39,40 These
implants produced 109.7 + 8.9 pg E2 and 4.27 + 0.37 ng pro-
gesterone /mL in serum in the macaques.
Subsequently, we studied normal controls (n ¼ 11) and
induced endometriosis models (n ¼ 14) across the menstrual
cycle utilizing artificial cycles. This induced model has been
previously described in detail.39,40 In order to study prolifera-
tive endometrium, endometrial tissues were collected via hys-
terectomy specimens from artificially cycled macaques treated
with E2 for 5 to 7 days following progesterone withdrawal. In
order to study secretory endometrium, endometrial tissues were
collected via hysterectomy specimens from artificially cycled
macaques treated with E2 plus progesterone for 14 days.
39,40
Animals with advanced endometriosis were diagnosed dur-
ing physical examination, and this diagnosis was confirmed by
conventional ultrasound, to identify sonographic features of
endometriomas, and needle biopsy, with aspiration of red-
and/or chocolate-colored fluids. Finally, all subjects had histo-
logic confirmation once surgical pathology was obtained at the
time of tissue procurement. Endometrium was collected by dis-
section from the uterus removed from the animals either during
the proliferative phase (mean E2 ¼ 145.5 + 16.3 pg/mL) or
during the secretory phase (mean progesterone ¼ 3.13 +
0.21 ng/mL).
For both control and endometriotic animals, the uterus was
dissected free of connective tissue adhesions and endometriotic
tissue, bisected along the longitudinal axis from the fundus to
cervix, and then further divided into quarters. Full-thickness
tissue sections (*5 mm) extending from the uterine lumen to
the outer myometrium were taken from each quarter. Tissue
blocks were fixed in 4% paraformaldehyde and subsequently
embedded in paraffin. The remaining endometrium was sepa-
rated from the outer myometrium with iris scissors, weighed,
and frozen separately in liquid nitrogen for subsequent mRNA
analysis.
Messenger RNA expression. Frozen samples of endometrial tis-
sue were thawed in 10 volumes of TRIzol (Invitrogen), and
total RNA was isolated, purified, and quality assessed as
described.41 Briefly, total RNA (1 mg) was reverse transcribed
with random hexamer primers (Promega Corporation, Madi-
son, Wisconsin) using an Omniscript RT kit (Qiagen, Valencia,
California). Transcript levels in each sample were quantified
against a 5-point standard curve, derived from pooled cDNA
from all samples, prepared by 1:10 serial dilution. The relative
transcript levels of CXCL13 were normalized to the expression
of S10. Each reaction contained TaqMan probe specific for
each gene of interest and was performed in MicroAmp Fast
Optical 96-well plates on an ABI 7500 Fast Real-time PCR
System. Real-time PCR reagents and TaqMan probes were pur-
chased from Applied Biosystems Inc. Primer and probe were
designed using Primer Express software (Applied Biosystems
Inc) and are as follows: CXCL13—forward, 50-TGTGTCCAA-
GAGAGCTCAGTCTTT-30, reverse, 50-GGCGAGATTT-
GAATT CGATCA-30, probe, 50-TCCCCAGACGCTTCA-30;
S10—forward, 50-AATGTGCCC AACCTTCATGTC-30,
reverse, 50-TCCAGG CAAACTGTTCCTTCA-30, probe, 50-
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TGAAGGCCATGCAGTCTCTCAAGTCCC-30. Data were
analyzed by Mann-Whitney U test, P < .05.
Immunohistochemistry. Localization of CXCL13 protein was
conducted on paraffin-embedded samples. Serial 5-mm sections
were cut and mounted on Superfrost Plus slides (Fisher Scien-
tific, Waltham, Massachusetts), deparaffinized in xylene, and
rehydrated stepwise in descending ethanol. Antigen retrieval
was performed by heating the sections in citrate buffer (pH
6.0) for 10 minutes in a pressure cooker. All steps were per-
formed at room temperature (*23C) unless noted otherwise.
Slides were rinsed in PBS, treated with 3% hydrogen peroxide
(in methanol) for 30 minutes to block endogenous peroxidases,
then incubated with normal serum (ABC-kit, Vector Labs) for
20 minutes to block nonspecific IgG reactions. Sections were
then incubated at 4C overnight with a goat polyclonal anti-
body raised to detect CXCL13 (R&D Systems); primary anti-
body was omitted from slides used as negative controls.
After overnight incubation with primary antibody, all slides
were rinsed in PBS (containing 0.075% nonionic detergent
BRIJ), incubated with normal serum for 20 minutes, and then
incubated with the biotinylated rabbit anti-goat IgG (Vector
Labs) for 30 minutes. The slides were rinsed with PBS, reacted
with avidin–biotin peroxidase reagents (for 60 minutes), and
rinsed in Tris buffer (pH 7.6). The slides were incubated in
0.025% diaminobenzidine to visualize antibody–antigen com-
plexes. Sections were then stabilized by incubating the slides
in 0.025% osmium tetroxide (for *1 minute). Sections were
counterstained with hematoxylin, dehydrated in ascending
ethanols, cleared through a series of xylene, and then sealed
under Permount.
Slides were viewed on a Zeiss AxioImager A.1 microscope
(Carl Zeiss, Inc., Oberkochen, Germany) with planapochro-
matic lenses. Digital photomicrographs were captured with a
Leica DFC 480 camera (Leica, Wetzlar, Germany). All photo-
micrographic plates were background adjusted, cropped, and
subsequently annotated in Photoshop Creative Suite 4 (Adobe
Systems, Seattle, Washington).
Ethical approval. Participants signed an informed consent for this
IRB-approved protocol. Animal care was provided by the
veterinary staff of the ONPRC Division of Comparative Med-




To examine the changes in the expression levels of CXCL13
across the menstrual cycle, endometrial biopsies were taken
from normal, reproductive-age women in proliferative (P;
n ¼ 17), early secretory (ES; n ¼ 8), mid-secretory (MS;
n ¼ 16), and late-secretory (LS; n ¼ 9) phases. The early/
mid/late portions of the secretory phase are defined as follows:
early LH þ2-5, mid LH þ6-10, and late LH þ11-14. No
patients were menstruating at the time of biopsy. Average par-
ticipants age was 25.5 years old (range ¼ 18-34 years old).
In these normal participants, CXCL13 expression was
highly cycle regulated, with median mid-secretory mRNA
expression nearly 60-fold greater than that seen in the prolifera-
tive phase (P < .001; Figure 1). Immunohistochemistry con-
firmed that protein expression mirrors the changes seen in
mRNA expression and localizes expression to both epithelium
and stroma (Figure 2). These findings strongly suggest that
changes in mRNA expression translate to changes in protein
abundance and that both epithelial and stromal CXCL13
expressions may be directly or indirectly stimulated by
progesterone.
Given the cycle variation between the proliferative phase
and the secretory phase, we compared CXCL13 expression in
the eutopic endometrium of healthy participants (n ¼ 50) to
that of women with endometriosis (n ¼ 27; Figure 3). The
patients with endometriosis had a mean age of 31.6 years
(range ¼ 21.4-39.2 years). All came from a prospectively
obtained population with unexplained infertility (normal male
partner, ovulatory cycles, and at least 1 patent fallopian tube).
Using the control proliferative phase samples as a reference
(C Proliferative), we compared this to proliferative phase sam-
ples from women with endometriosis (Endo Proliferative) and
find that CXCL13 is significantly increased. Upon examining
the secretory samples, we find that both control (C) and endo-
metriosis (Endo) samples display increased levels of CXCL13
Figure 1. C-X-C ligand 13 (CXCL13) gene expression increases dur-
ing the secretory phase of the normal human menstrual cycle. Relative
expression levels of CXCL13 messenger RNA (mRNA) shown by real-
time polymerase chain reaction (PCR) in controls (n ¼ 50) across the
menstrual cycle. P, proliferative (n ¼ 17); ES, early secretory (n ¼ 8);
MS, mid-secretory (n¼ 16); LS, late secretory (n¼ 9). Median lines are
shown and box incorporates 75% of the samples. * indicates P < .001
by Kruskal-Wallis test compared to P.
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with no additional increase seen in endosecretory samples. In
the proliferative phase, the controls demonstrated a consistent,
low level of CXCL13 expression, while the samples from
patients with endometriosis exhibited a wide range of expres-
sion levels, with a 10-fold median increase and a greater than
1000-fold maximal increase. Importantly, the maximum level
seen in the controls was less than the 25th percentile in patients
with endometriosis in the proliferative phase.
Immunolocalization of CXCL13 in the proliferative endo-
metrium of participants without endometriosis displayed mini-
mal expression of CXCL13 protein that mirrored the
quantitative mRNA data. Immunolocalization of CXCL13 in
the proliferative endometrium of patients with endometriosis
showed expression primarily in the glandular and luminal
epithelium with intensities proportional to changes seen in
mRNA levels (Figure 4). These findings demonstrate that many
women with endometriosis have increased epithelial CXCL13
expression in the proliferative phase.
Rhesus Macaque Subjects
Given the significant findings in human endometrium, we next
examined endometrial samples from healthy Rhesus macaques
and compared them to samples of Rhesus macaques with con-
comitant naturally occurring endometriosis to examine cross-
species concordance. We initially examined endometrial tissue
from Rhesus macaques with (n¼ 7) and without (n¼ 11) endo-
metriosis. In the controls, the mean age was 9.8 years(range ¼
6.6-12.1 years) and in the naturally occurring endometriosis the
mean age was 13.9 years (range ¼ 10.22-18.10 years). The
mRNA data from macaques mirrored that from humans in that
there was a significant increase in overall expression of CXCL13
in the endometrium of macaques with endometriosis (Figure 5).
Figure 2. C-X-C ligand 13 (CXCL13) protein is expressed in the glandular and stromal compartments of normal human endometrium. Rep-
resentative photomicrographs demonstrating CXCL13 expression in endometrial biopsies from normal, reproductive-age women in the pro-
liferative phase (A) and the secretory phase (B). CXCL13 immunohistochemically stains brown and the nuclei are counterstained blue with
hematoxylin. Representative photomicrographs of human endometrium are shown at 200 magnification. (The color version of this article
is available at http://rs.sagepub.com.)
Figure 3. C-X-C ligand 13 (CXCL13) gene expression increases
aberrantly during the proliferative phase of the menstrual cycle in
women with endometriosis. CXCL13 messenger RNA (mRNA)
expression from control proliferative (C Proliferative) and control
secretory (C Secretory). Endometriosis proliferative (Endo Prolifera-
tive) and endometriosis secretory (Endo Secretory) phases of the men-
strual cycle were compared from patients with endometriosis (Endo)
and control endometriosis-free, reproductive-age controls (C) shown
by real-time PCR. Median lines are shown and box incorporates 75% of
the samples. * indicates P < .001 by Dunn Multiple Comparison test
comparing control samples in the control proliferative phase to other
groups. The maximum level seen in the control proliferative samples
was below the lowest 25th percentile in patients with endometriosis.
Control proliferative (C Proliferative; n ¼ 17); endometriosis prolif-
erative (Endo Proliferative; n ¼ 12); control secretory (C Secretory;
n ¼ 33); endometriosis secretory (Endo Secretory; n ¼ 15).
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To then more closely examine at what stage the CXCL13
was aberrantly expressed in macaques with endometriosis,
samples from proliferative and secretory groups were exam-
ined in subjects with surgically induced endometriosis. Sam-
ples analyzed were from the proliferative phase (n ¼ 3) and
secretory phase (n ¼ 9) and in the endometriosis-free control
animals and the proliferative phase (n¼ 6) and secretory phase
(n ¼ 8) from the induced endometriosis group. The induced
endometriosis group was more closely age matched with the
control group and had a mean age of 10.4 years (range ¼
7.7-12.8 years). However, we did not see the cycle-related dif-
ferences noted in human endometrium (Figure 6A). Although
macaques with endometriosis demonstrated a 2.7-fold mean
increase in CXCL13 mRNA in proliferative phase samples
when compared to proliferative phase controls (Figure 6A), this
apparent change did not reach statistical significance, most
likely due to a limited number of subjects in the proliferative
control group. However, a more consistent and somewhat
higher (3-fold) significant increase was seen in the late secre-
tory macaque samples with endometriosis when compared to
controls (Figure 6A). Immunohistochemistry for CXCL13 con-
firmed expression of protein in the glandular and luminal
epithelium, which mirrored the increased mRNA levels by
quantitative real-time PCR (Figure 6B). Thus, cycle-phase
effects on normal macaque endometrial expression of CXCL13
were not detected, but importantly, endometriosis was corre-
lated with increased CXCL13 expression.
Discussion
In this study, we analyzed the changes in human endometrial
CXCL13 expression across the normal menstrual cycle,
demonstrating maximal expression in the secretory phase and
minimal expression in the proliferative phase. Mid-secretory
phase endometrial CXCL13 expression in women with endo-
metriosis versus controls was similar, while proliferative phase
expression in women with endometriosis was dramatically ele-
vated. Indeed, the maximum level seen in the controls was less
than the 25th percentile in women with endometriosis. To our
knowledge, this is the first account demonstrating upregulation
of CXCL13 expression in the secretory phase of the normal,
human menstrual cycle and, the first demonstration of
increased expression of CXCL13 in the endometrium of
humans and macaque subjects with endometriosis. The cross-
species data concordance strongly supports the hypothesis that
endometrial CXCL13 expression plays an important role in the
pathophysiology of the disease.
Figure 4. C-X-C ligand 13 (CXCL13) protein is expressed in the glandular and stromal compartments of proliferative phase endometrium in
women with endometriosis. Representative photomicrographs demonstrating CXCL13 expression in normal (A) and in endometriosis (B) in
reproductive-age women in the proliferative phase. CXCL13 immunohistochemically stains brown and the nuclei are counterstained blue with
hematoxylin. Representative photomicrographs of human endometrium are shown at 200 magnification.
Figure 5. C-X-C ligand 13 (CXCL13) gene expression increases in
the endometrium of Rhesus macaques with naturally occurring endo-
metriosis. Endometrium from macaques with endometriosis and
those without was analyzed for CXCL13 messenger RNA (mRNA)
by real-time polymerase chain reaction (PCR). * indicates P < .05 by
Mann-Whitney U test.
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In contrast, the microarray data in Burney et al showed that
CXCL13 expression was reduced in women with endometriosis,
but those findings were confined to the secretory phase.35 The
reasons for these differences are unclear, but given the greater
precision of PCR versus microarray and the general concor-
dance between immunohistochemistry and PCR, we believe that
the data in our report are likely more generalizable.
The largest fold changes between patients with endometrio-
sis and controls were seen in the proliferative phase human
samples. The finding of proliferative phase changes is interest-
ing in that most studies have examined the secretory phase.42
However, a few recent articles have suggested a proliferative
phase abnormality in women with endometriosis.36,43 Specifi-
cally, Bromer et al introduced sonographic evidence of altera-
tions in proliferative phase endometrial thickness supporting a
‘‘proliferative phase defect’’ in patients with endometriosis and
other specific causes of infertility.36 Petracco et al found prolif-
erative phase expression of specific microRNA species altered
in endometriosis.43 Our findings lend further molecular and
histologic evidence that an endometrial abnormality in women
with endometriosis can be seen in the proliferative phase, a
time when abnormalities are independent of an altered response
to progesterone.35,44,45
The specific role that CXCL13 might play in the endome-
triosis disease processes is unclear, but knowledge of CXCL13
effects in other systems may be instructive. C-X-C ligand 13 is
a chemokine that is strongly expressed in the follicles of the
spleen, lymph nodes, and Peyer patches and preferentially pro-
motes the migration of B lymphocytes (especially B-1 cells)
when compared to T lymphocytes and macrophages.46 Indeed,
CXCL13 plays an important role in migratory synergism for
homeostatic responses and a pronounced role in inflammatory
trafficking of B cells.47-49 In addition, elevated CXCL13 pro-
duction has also been shown to be correlated with autoimmune
disease.50-56 These findings may be directly relevant to endo-
metriosis, given the growing body of data detailing the intimate
association between the immune system and endometriosis
pathophysiology.57-60 Thus, CXCL13 misexpression adds to
our understanding of this complex interplay between the
immune system, endometriosis, and infertility.
C-X-C ligand 13 also plays a role in cancer adhesion and
invasion, which might be considered an analogous process to the
endometrial tissue adherence and invasion into the peritoneum
in women with endometriosis. In prostate cancer, CXCL13
induces cell adhesion and invasion in a CXCR5-dependent
manner.61,62 In breast cancer, CXCL13 is overexpressed with
elevated levels found in the serum of patients with metastatic
disease.63 Additionally, CXCL13 can play a role in cellular traf-
ficking. Neural precursor cells are able to cross the brain
endothelium in response to interleukin 8 and CXCL13 and play
a role in vascular inflammation and leukocyte recruitment.64,65
Thus, CXCL13 might play a chemotactic role for the localiza-
tion, adherence, and/or invasion of endometriosis lesions.
Finally, CXCL13’s role in cell migration and tissue invasion
has implications in successful embryo implantation. Our data indi-
cate that CXCL13 expression in the human is cycle regulated and
increased in the secretory phase, including the window of implan-
tation. The interplay between CXCL13 and the embryo has been
partially characterized in that CXCL13 is both secreted by human
endometrial epithelium and specifically taken up by embryos with
high implantation potential.32 However, it is unclear whether the
blastocyst internalizes CXCL13 in a receptor-mediated process
or is simply metabolized. Thus, the hypothesis that CXCL13 plays
a chemotactic role in trophoblast invasion is attractive but requires
significantly more investigation.
In summary, the potential roles for CXCL13 in normal and
abnormal reproductive processes are many and include embryo
implantation, embryo selection during IVF cycles, endometrio-
sis pathophysiology, and endometriosis diagnosis. However,
further investigations are needed to more clearly elucidate
CXCL13’s specific role in these processes. A murine model
may allow for detailed mechanistic studies of endometriosis
development and allow testing of therapeutic drugs targeted
to the CXCL13 signaling pathway. One exciting possibility
suggested by the definitive dysregulation of CXCL13 in the
proliferative phase of many patients with endometriosis is that
CXCL13 could serve as a specific diagnostic marker. Further
studies are being undertaken by our group to test the clinical
usefulness of measuring CXCL13 expression in endometrial
Figure 6. C-X-C ligand 13 (CXCL13) increases in Rhesus macaques
with endometriosis in the proliferative and secretory phases of the
menstrual cycle. A, CXCL13 messenger RNA (mRNA) expression
was analyzed in the proliferative phase (n ¼ 3) and secretory phase
(n ¼ 9) and from endometriosis-free control animals in the prolifera-
tive phase (n ¼ 6) and secretory phase (n ¼ 8). Bars marked ‘‘a’’
are P < .05 versus those marked ‘‘b’’ by analysis of variance
(ANOVA) and Neumann-Keuls post hoc testing. B, Representative
photomicrographs demonstrating immunohistochemical staining
for CXCL13 in the proliferative phase and secretory phase of the
menstrual cycle in Rhesus macaques. CXCL13 staining is brown
and the nuclei are counterstained blue with hematoxylin. Insets are
negative controls with primary antibody omitted.
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biopsy material as well as in a less invasive cervical swab,
given the secretion of CXCL13 protein by luminal epithelium.
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